Evidence map›Paper›PMID 36311556›Full record

ArticleInorganic chemistry frontiers2022

Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity.

Mickaël Marloye, Haider Inam, Connor J Moore, Tyler R Mertens, Aude Ingels, Marilin Koch, Michal O Nowicki, Véronique Mathieu, Justin R Pritchard, Samuel G Awuah and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inorganic chemistry frontiers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Mickaël MarloyeMicrobiology, Bioorganic & Macromolecular Chemistry, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
Haider InamDepartment of Biomedical Engineering, Pennsylvania State University, University Park, PA 16802, USA.
Connor J MooreDepartment of Biomedical Engineering, Pennsylvania State University, University Park, PA 16802, USA.
Tyler R MertensDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Aude IngelsDepartment of Pharmacotherapy and Pharmaceutics, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
Marilin KochHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Michal O NowickiHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Véronique MathieuDepartment of Pharmacotherapy and Pharmaceutics, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
Justin R PritchardDepartment of Biomedical Engineering, Pennsylvania State University, University Park, PA 16802, USA.
Samuel G AwuahDepartment of Chemistry, University of Kentucky, Lexington, KY 40506, USA.
Sean E LawlerHarvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Franck MeyerMicrobiology, Bioorganic & Macromolecular Chemistry, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
François DufrasneMicrobiology, Bioorganic & Macromolecular Chemistry, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
Gilles BergerMicrobiology, Bioorganic & Macromolecular Chemistry, Faculté de Pharmacie, Université libre de Bruxelles (ULB), Boulevard du Triomphe, 1050 Brussels, Belgium.
Université Libre de Bruxelles · BEBrigham and Women's Hospital · USPennsylvania State University · USUniversity of Kentucky · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Gold-derived Therapeutic Compounds for Disease ApplicationR01CA258421 · NCI · UNIVERSITY OF KENTUCKY · PI AWUAH, SAMUEL GORMAN · 2021 to 2025
$1.7M
Innovative approaches for the advancement of glioblastoma therapiesR50CA243706 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NOWICKI, MICHAL OSKAR · 2019 to 2023
$662k
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA258421NCI NIH HHS R50 CA243706
6 · The paper itself

Abstract

We disclose novel amphiphilic ruthenium and osmium complexes that auto-assemble into nanomedicines with potent antiproliferative activity by inhibition of mitochondrial respiration. The self-assembling units were rationally designed from the [M(

Indexed as

antitumor complexesCancer stem cellsMetabolic poisonsnano-assemblingshRNA profiling

Identifiers

PMID36311556
PMCPMC9610622
OpenAlexW4226248850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.